Khalid AL. Naamani: Efficacy, Safety, and Patient Selection of DOACs in Cirrhosis
Khalid AL. Naamani, Executive Committee Member Ministry of Health Oman, Chairman of The Medical City for Military and Security Services, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
”I’m pleased to share our recent publication: Direct Oral Anticoagulants for Portal Vein Thrombosis in Cirrhosis: From Pharmacology to Clinical Practice
In this review, we explore the evolving role of direct oral anticoagulants (DOACs) in the management of portal vein thrombosis (PVT) in patients with cirrhosis.
Key highlights:
- Hemostasis in cirrhosis is a complex, rebalanced state rather than a simple bleeding tendency
- DOACs offer a promising alternative to traditional anticoagulants, with convenient fixed dosing and favorable safety profiles
- Evidence suggests comparable – and in some cases superior – recanalization rates versus VKAs, without a significant increase in major or variceal bleeding
- Careful patient selection remains essential, particularly based on liver function (CTP classification), renal status, and transplant candidacy
While current data are encouraging, further prospective studies are still needed, especially in patients with more advanced cirrhosis.
Grateful to my co-authors and collaborators for their valuable contributions to this work.”
Title: Direct Oral Anticoagulants for Portal Vein Thrombosis in Cirrhosis: From Pharmacology to Clinical Practice
Authors: Khalid M. Al Naamani, Sundus Rizwan, Siham Al Sinani, Bader Al Rawahi, Sheikha AlMa’mari, Mohamed El-Kassas
Read the Full Article on Clinical and Applied Thrombosis/Hemostasis
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 13, 2026, 02:01Nour Al-Mozain: Is It Really Anti-D? – Unraveling Auto-Anti-LW in the Transfusion Laboratory
-
Oct 13, 2026, 01:51Berenice Villegas: The Role of Morphologic Evaluation in Body Fluid Differential Analysis
-
Oct 13, 2026, 01:44Debadrita Ray: Evaluating vWF and VITRO Score for Detecting CSPH in cACLD Patients
-
Oct 13, 2026, 01:34Nagesh Ramesh: Donating Blood for International Plasma Awareness Week
-
Oct 12, 2026, 21:51Sam Botchey: Orthobiologics Are Advancing but the Evidence Must Keep Pace
-
Oct 12, 2026, 21:50Serum Vitamin D, Platelet Function, and Bleeding in Primary ITP – Platelets Journal
-
Oct 12, 2026, 21:30Nika Samadzadeh Tabrizi: Looking Forward to the PACeS Trial on Anticoagulation for POAF
-
Oct 12, 2026, 21:28Michael Megaly: Does Coronary Ectasia Affect Outcomes in Acute Coronary Syndromes?
-
Oct 12, 2026, 21:25Vitor Borin P. de Souza: Think Twice Before Anticoagulating an Isolated Subsegmental PE